Your English writing platform
Discover LudwigExact(31)
In this study, we illustrate that TR derivatives show reactivation of the HER pathway as a mechanism of resistance.
Thus the combination regimen is highly effective in suppressing the HER pathway in most HER2-overexpressing models.
Several drugs have been developed and are in clinical use to block the HER pathway, most aimed at the receptor level.
As in the prior studies, LRes and LTRes cells have low levels of phosphorylated HER2, EGFR, and HER3, indicating that the HER pathway is still shut down.
The increased protein levels of ER and PR observed in BT474 LR cells decreased in BT474 LLR, as the HER pathway became active once more.
Collectively, we did show that TR derivatives are still dependent on the HER pathway and, therefore, remain sensitive to L, as previously reported [ 44].
Similar(29)
We also observed the recovery of phospho-PKB (Ser473) and phospho-ERK1/2 within 48 hours (Figure 3B, lower panels), consistent with activation of alternative HER pathways including HER2/HER3 and HER2/HER4 via autocrine release of ligands.
Dual targeting of mTOR and upstream HER pathways, along with endocrine therapy, is likely to be more effective.
The crosstalk between the oestrogen receptor pathway and growth factor pathways, such as the HER pathways, is a prime example of ongoing research.
In addition, the IGF pathway as well as other human epidermal growth factor receptor (HER) pathways are present and thought to be active in ovarian cancer (Hamburger, 2001; Mayr et al., 2006).
When selected cell lines are treated with HER2 inhibitors, we not only observe the expected molecular effects based on mechanism of action knowledge, but also novel effects of HER2 inhibition on key targets in the HER receptor pathway.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com